title: Does letrozole have any place in adjuvant setting in breast cancer patients with documented hypercoagulability?
authors.forename: Basak
authors.initials: B
authors.lastname: Oyan
authors.forename: Kadri
authors.initials: K
authors.lastname: Altundag
authors.forename: Yavuz
authors.initials: Y
authors.lastname: Ozisik
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D047072:Aromatase Inhibitors; D001943:Breast Neoplasms / Q000150:complications* / Q000188:drug therapy*; D000075202:Contraindications; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000077289:Letrozole; D009570:Nitriles / Q000627:therapeutic use*; D011655:Pulmonary Embolism / Q000209:etiology*; D012306:Risk; D013629:Tamoxifen / Q000009:adverse effects; D014230:Triazoles / Q000627:therapeutic use*; D020246:Venous Thrombosis / Q000150:complications* / Q000188:drug therapy; D014859:Warfarin / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D000970:Antineoplastic Agents; D047072:Aromatase Inhibitors; D004791:Enzyme Inhibitors; D009570:Nitriles; D014230:Triazoles; D013629:Tamoxifen; D014859:Warfarin; D000077289:Letrozole